Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, helping to provide hope to patients and their families around the world. For more than 35 years, we have been a pioneer and innovator in rare genetic diseases.
Lysosomal storage disorders (LSDs) are a family of over 50 genetic diseases and an area of expertise for us – particularly Gaucher, Fabry, Pompe and Mucopolysaccharidosis (MPS) I and II diseases. LSDs are individually rare but collectively more common with high unmet need. We are continuing to research and develop new therapies for LSDs while leveraging our expertise to expand our focus to other rare conditions.
Sanofi Genzyme is dedicated to improving patients’ access to early diagnosis and appropriate treatment. Our support for patients extends beyond our therapies. We work to improve the diagnosis of rare diseases through physician education, disease awareness programs, by providing free testing for patients, and supporting screening initiatives and patient support programs.
We take this opportunity to introduce the Wiley Professional Academy Online Certification Learning Programme.
This online learning programme will feature the following adaptive learning modules. Click any module below to begin the course
We hope this learning will be of interest to you and add value to your practice. We look forward to your participation.
Team Sanofi Genzyme
Sanofi-aventis Australia pty ltd trading as Sanofi Genzyme
ABN 31 008 558 807. Talavera Corporate Centre, Building D,
12-24 Talavera Road, Macquarie Park, NSW 2113.
MAT-AU-2100135. Date of Preparation: February 2021